FDA approves denosumab for prevention of SREs in patients with bone metastases from solid tumors - - Drug Topics
Links shared publicly online about this topic.
- 715total visits
FDA approves denosumab for prevention of SREs in patients with bone metastases from solid tumors - - Drug Topics
drugtopics.modernmedicine.com —
FDA has approved denosumab (Xgeva, Amgen), the first and only RANK Ligand inhibitor for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. Xgeva was approved following a 6-month priority review by FDA. Xgeva is not indicated for the prevention of SREs in patients with multiple myeloma.
View full resource at drugtopics.modernmedicine.com
Tags: Bone Cancer, Bone Metastasis, Bone, Osteoporosis Medication, FDA, Prolia, News
Most Recently Shared on November 19, 2010 at 5:37 pm By:
Breaking news: FDA approves denosumab for prevention of SREs in patients with bone metastases from solid ... http://bit.ly/97jcLx #drug
Advertisement
